Preclinical and in vitro studies of recombinant factor VIIi
Fournel, M.A.
Seminars in Hematology 28(2 Suppl 1: 22-26
1991
ISSN/ISBN: 0037-1963 PMID: 1908122 Document Number: 384643
Document emailed within 1 workday
Related Documents
Mahasandana, C.; Suvatte, V.; Püng-amritt, P.; Tuchinda, S. 1979: Von Willebrand's disease: studies of platelet functions, factor VIII procoagulant activity (F VIII C) and factor VIII-related antigen (F VIII RAg) in three families Southeast Asian Journal of Tropical Medicine and Public Health 10(2): 243-247Schaub, R.; Garzone, P.; Bouchard, P.; Rup, B.; Keith, J.; Brinkhous, K.; Larsen, G. 1998: Preclinical studies of recombinant factor IX Seminars in Hematology 35(2 Suppl 2: 28-32
Lee, C.A.; Owens, D.; Bray, G.; Giangrande, P.; Collins, P.; Hay, C.; Gomperts, E.; Schroth, P.; Barrowcliffe, T. 1999: Pharmacokinetics of recombinant factor VIIi (recombinate) using one-stage clotting and chromogenic factor VIIi assay Thrombosis and Haemostasis 82(6): 1644-1647
Fijnvandraat, K.; Berntorp, E.; ten Cate, J.W.; Johnsson, H.; Peters, M.; Savidge, G.; Tengborn, L.; Spira, J.; Stahl, C. 1997: Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients Thrombosis and Haemostasis 77(2): 298-302
Brown, J.E.; Carton, C.L.; Hougie, C. 1981: The effect of naturally occurring antibodies to factor VIIi on an immunoradiometric assay for factor VIIi coagulant antigen. Observation on a cross-reacting material-positive (CRM+) hemophiliac with a factor VIIi inhibit Journal of Laboratory and Clinical Medicine 97(1): 65-71
Arrighi, S.; Rossi, R.; Borri, M.G.; Lesnikov, V.; Lesnikova, M.; Franco, E.; Divizia, M.; De Santis, M.E.; Bucci, E. 1995: "In vitro" and in animal model studies on a double virus-inactivated factor VIII concentrate Thrombosis and Haemostasis 74(3): 868-873
Takahashi, I.; Furuta, M.; Mizuno, S.; Takamatsu, J.; Kamiya, T. 1993: Effect of substrate and diluent for factor VIIi activity in highly purified factor VIIi concentrate and patient plasma infused factor VIIi concentrate Rinsho Byori. Japanese Journal of Clinical Pathology 41(7): 825-830
Muntean, W. 1984: Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma Wiener Klinische Wochenschrift 96(22): 829-832
Tusell, J.M. 1993: Recombinant factor VIIi Sangre 38(2): 139-142
Tran, T.H.; Duckert, F. 1983: Dissociation of factor VIIi procoagulant antigen VIII:CAg and factor VIIi related antigen VIIIR:Ag by EDTA - influence of divalent cation on the binding of VIII:CAg and VIIIR:Ag Thrombosis and Haemostasis 50(2): 547-551
Klein, U. 1991: Production and characterization of recombinant factor VIIi Seminars in Hematology 28(2 Suppl 1: 17-21
Berntorp, E. 1997: Second generation, B-domain deleted recombinant factor VIII Thrombosis and Haemostasis 78(1): 256-260
Hilgartner, M.W. 1991: The need for recombinant factor VIII: historical background and rationale Seminars in Hematology 28(2 Suppl 1: 6-9
Schwartz, R.S.; Rousell, R.H. 1991: A summary of the world-wide clinical investigations of recombinant factor VIII Seminars in Hematology 28(2 Suppl. 1): 53-54
Briseid, G.; Arntzen, F.C. 1995: Factor VIIi preparation produced by recombinant DNA-technology is approved in Norway Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 115(15): 1849-1851
Eis-Hübinger, A.M.; Sasowski, U.; Brackmann, H.H.; Kaiser, R.; Matz, B.; Schneweis, K.E. 1996: Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIIi products Thrombosis and Haemostasis 76(6): 1120
Bugelski, P.J.; Treacy, G. 2004: Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans Current Opinion in Molecular Therapeutics 6(1): 10-16
Teitel, J.M.; Lau, H.K.; Garvey, M.B. 2002: Discrepancies in measured factor VIIi activity in patients treated with factor VIIi concentrate of human or porcine origin Thrombosis and Haemostasis 88(1): 159-160
Liebe, S. 1982: Activation of the antihemophilic globulin a (factor VIII). 2. Effect of ampholine on the course of blood coagulation and the molecular conformation of factor VIIi Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 37(4): 110-116
Brettler, D.B.; Forsberg, A.D.; Levine, P.H.; Aledort, L.M.; Hilgartner, M.W.; Kasper, C.K.; Lusher, J.M.; McMillan, C.; Roberts, H. 1989: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Archives of Internal Medicine 149(6): 1381-1385